Inhibition of angiogenesis by internalization inducer
Project/Area Number |
23590459
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Experimental pathology
|
Research Institution | Osaka University |
Principal Investigator |
NARAZAKI Masashi 大阪大学, 医学(系)研究科(研究院), 助教 (00467573)
|
Project Period (FY) |
2011 – 2013
|
Project Status |
Completed (Fiscal Year 2013)
|
Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2012: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2011: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
Keywords | 血管新生 / Neuropilin-1 / 血管内皮細胞 / 受容体 / Neuropilin1 / VEGF |
Research Abstract |
We analyzed the inhibitory mechanisms of angiogenesis by using three groups of molecule, including artificial compounds, physiological cytokine, and inhibitory antibody. Neuropilin-1 is a cell surface receptor of VEGF. We showed that sulfate polysaccharide, fucoidan, and oligo-guanosine nucleotide could internalize Neuropilin-1 from the endothelial cell surface to lysosome as an "internalization-inducer". Moreover, we showed that fucoidan and oligo-guanosine nucleotide could inhibit angiogenesis in vivo. We analyzed the interaction of a cytokine VEGF-B with FGF receptor. We proposed the possibility that VEGF-B works as an antagonist of FGF receptor. And we analyzed the biochemical property of the antibody against the members of Ephrin family that are recently identified to have a role in angiogenesis.
|
Report
(4 results)
Research Products
(19 results)
-
-
[Journal Article] Expansion of range of joint motion following treatment of systemic sclerosis with tocilizumab.2014
Author(s)
Shima Y, Hosen N, Hirano T, Arimitsu J, Nishida S, Hagihara K, Narazaki M, Ogata A, Tanaka T, Kishimoto T, Kumanogoh A.
-
Journal Title
Mod Rheumatol.
Volume: Feb 18
Related Report
Peer Reviewed
-
-
-
-
[Journal Article] Retention of tocilizumab and anti-tumour necrosis factor drugs in the treatment of rheumatoid arthritis.2013
Author(s)
Hishitani Y, Ogata A, Shima Y, Hirano T, Ebina K, Kunugiza Y, Shi K, Narazaki M, Hagihara K, Tomita T, Yoshikawa H, Tanaka T, Kumanogoh A.
-
Journal Title
Scand J Rheumatol.
Volume: 42(4)
Pages: 253-259
Related Report
Peer Reviewed
-
-
-
-
-
[Journal Article] A case of Behçet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab.2012
Author(s)
Hirano T, Ohguro N, Hohki S, Hagihara K, Shima Y, Narazaki M, Ogata A, Yoshizaki K, Kumanogoh A, Kishimoto T, Tanaka T.
-
Journal Title
Mod Rheumatolol
Volume: 22(2)
Pages: 298-302
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-